Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

Chemistry lab worker

Our Mission

Derived from the Finnish word for “to serve”, Palvella Therapeutics was founded to serve individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.

Our Programs

Microcystic LM

Microcystic Lymphatic Malformations (Micro LM) is a rare genetic disease of the lymphatic system characterized by abnormal vessels or cysts that leads to chronic lymphorrhea, bleeding, pain, and a risk of severe life-threatening infections. There are no FDA approved therapies. Palvella has successfully completed a Phase 2 clinical study for QTORIN™ rapamycin 3.9%, for people with this disease. Palvella has been awarded FDA Breakthrough Therapy Designation, FDA Orphan Drug, and Fast Track Designation for this program.

Gorlin Syndrome

Gorlin syndrome is a serious rare genetic disease where people may develop thousands of basal cell carcinomas, a form of cancerous skin tumors. There are no FDA approved therapies. Palvella is conducting a phase 2b clinical study of QTORIN™ rapamycin 3.9% for people with Gorlin syndrome, has been awarded FDA Fast Track designation.

Other Vascular Malformations

Palvella is continuing research into other mTOR-driven diseases, building on our clinical experience with QTORIN Rapamycin.

We’re uncovering more therapies every day. Stay updated.

Listen to Braham Shroot, Chief Scientific Officer

Our People

We are innovators, scientists, and doers. Palvella brings together individuals with expertise in rare genetic diseases,  formulation development, drug manufacturing, and clinical development. Most of all, we are unified in our passion and commitment to writing a new future for those suffering from rare diseases.

Treating the Root Cause

Our approach is to first select the diseases most in need; where the disease impact is constant, and treatments are limited. We collaborate with key researchers globally to define the root cause of the disease, then develop targeted therapies that address the genetic defect.